BR0212897A - Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos - Google Patents

Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos

Info

Publication number
BR0212897A
BR0212897A BR0212897-7A BR0212897A BR0212897A BR 0212897 A BR0212897 A BR 0212897A BR 0212897 A BR0212897 A BR 0212897A BR 0212897 A BR0212897 A BR 0212897A
Authority
BR
Brazil
Prior art keywords
peptide
diagnostic
somatostatin
therapeutic
agents
Prior art date
Application number
BR0212897-7A
Other languages
English (en)
Inventor
David H Coy
Joseph A Fuselier
William A Murphy
Lichun Sun
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of BR0212897A publication Critical patent/BR0212897A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

"CONJUGADOS DE ANáLOGOS DE SOMATOSTATINA OU BOMBESINA DIAGNóSTICA OU TERAPêUTICA E USOS DOS MESMOS". A invenção refere-se a agentes peptídicos e usos dos mesmos que são análogos de peptídios biologicamente ativos como somatostatina e bombesina. Os compostos da invenção têm a fórmula geral X-Y-Z-Q, onde X é um agente citotóxico, um agente terapêutico, um marcador detectável ou um grupo quelante, e Q é um peptídio biologicamente ativo. Nos agentes peptídicos da invenção Y é opcionalmente um polímero ou peptídio hidrófilo, e Z é um peptídio de ligação ligado a Q no terminal amino de Q, tendo dois, três, quatro ou cinco resíduos de aminoácidos selecionados para ligar X a Q, retendo a atividade biológica de Q. Também estão descritos métodos de uso desses agentes peptídicos para diagnóstico e tratamento de doenças.
BR0212897-7A 2001-09-21 2002-09-20 Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos BR0212897A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32385101P 2001-09-21 2001-09-21
PCT/US2002/030143 WO2003028527A2 (en) 2001-09-21 2002-09-20 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Publications (1)

Publication Number Publication Date
BR0212897A true BR0212897A (pt) 2004-08-24

Family

ID=23260992

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212897-7A BR0212897A (pt) 2001-09-21 2002-09-20 Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos

Country Status (16)

Country Link
US (1) US7326685B2 (pt)
EP (1) EP1435826A4 (pt)
JP (1) JP4799820B2 (pt)
KR (1) KR20040047846A (pt)
CN (1) CN1589151A (pt)
AU (1) AU2002341792B2 (pt)
BR (1) BR0212897A (pt)
CA (1) CA2461099A1 (pt)
IL (2) IL160993A0 (pt)
IS (1) IS7189A (pt)
MX (1) MXPA04002621A (pt)
NO (1) NO20041186L (pt)
NZ (1) NZ532204A (pt)
PL (1) PL369336A1 (pt)
WO (1) WO2003028527A2 (pt)
ZA (1) ZA200402698B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6721705B2 (en) * 2000-02-04 2004-04-13 Webley Systems, Inc. Robust voice browser system and voice activated device controller
DK1487493T3 (da) 2002-03-01 2010-05-25 Univ Tulane Konjugater af cytotoksiske midler og biologisk aktive peptider
US8060626B2 (en) * 2008-09-22 2011-11-15 Sony Computer Entertainment America Llc. Method for host selection based on discovered NAT type
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
SG173223A1 (en) * 2003-04-22 2011-08-29 Ipsen Pharma Sas Peptide vectors
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050255045A1 (en) * 2004-05-13 2005-11-17 Woltering Eugene A Surgical marking composition and method
AU2005244037A1 (en) * 2004-05-14 2005-11-24 Interface Biologics Inc. Polymeric coupling agents and pharmaceutically-active polymers made therefrom
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
AU2005262472B2 (en) * 2004-06-16 2011-10-27 President And Fellows Of Harvard College Methods and compositions for modulating bax-mediated apoptosis
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
JP5235662B2 (ja) * 2005-06-16 2013-07-10 ミリアド ジェネティクス， インコーポレイテッド 薬学的組成物およびその使用
US8735177B2 (en) 2006-02-23 2014-05-27 Adeka Corporation Diagnostic marker
DE102006035083A1 (de) * 2006-07-28 2008-01-31 medac Gesellschaft für klinische Spezialgeräte mbH Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
SI2076535T1 (sl) 2006-10-16 2013-07-31 The Salk Institute For Biological Studies Antagonisti somatostatina, selektivni za receptor (SSTR2)
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
WO2008051421A2 (en) * 2006-10-20 2008-05-02 Ipsen Pharma S.A.S. Peptide-cytotoxic conjugates
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CN101742910A (zh) * 2007-04-10 2010-06-16 美瑞德制药公司 治疗脑癌的方法
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
WO2008124823A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Method of treating melanoma
CN103501823B (zh) 2011-02-17 2018-05-04 杜兰教育基金委员会 多组分组合物以及它们的用途
CN110420333A (zh) 2013-03-14 2019-11-08 斯克利普斯研究所 靶向剂抗体偶联物及其用途
CA3013882A1 (en) 2016-02-09 2017-08-17 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same
WO2017165607A1 (en) 2016-03-24 2017-09-28 The Administrators Of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
KR20200121816A (ko) 2018-02-02 2020-10-26 리플 테라퓨틱스 코포레이션 스테로이드 이량체를 포함하는 유리 제제 및 이의 용도
JP7368854B2 (ja) * 2018-03-15 2023-10-25 国立大学法人大阪大学 ２１１Ａｔ標識化アミノ酸誘導体を含む医薬組成物及びその製造方法
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US5073541A (en) * 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
US5753627A (en) 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5633263A (en) 1989-04-26 1997-05-27 The Administrators Of The Tulane Educational Fund Linear somatostatin analogs
HU219336B (en) 1989-07-20 2001-03-28 Novartis Ag Process for producing peptide derivatives and pharmaceutical compositions comprising such compounds and diagnostic unit containing such compounds
ES2075244T3 (es) * 1990-04-06 1995-10-01 Univ Tulane Analogos de la somatostatina.
US5443815A (en) 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5411943A (en) 1992-02-25 1995-05-02 Biomeasure, Inc. Hepatoma treatment with somatostatin analogs
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5708135A (en) 1995-09-29 1998-01-13 Biomeasure Incorporated Cyclic peptide analogs of somatostatin
US5750499A (en) 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5843903A (en) 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US6156725A (en) * 1996-08-16 2000-12-05 National Institute Of Immunology Drug for the treatment of cancer
EP0977579B1 (en) 1997-04-22 2009-03-11 Curator Of The University Of Missouri Gastrin receptor-avid peptide conjugates
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
CA2449634C (en) * 2001-06-08 2011-08-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Somatostatin-dopamine chimeric analogs

Also Published As

Publication number Publication date
PL369336A1 (en) 2005-04-18
MXPA04002621A (es) 2004-07-08
WO2003028527A8 (en) 2004-04-15
IS7189A (is) 2004-03-19
CN1589151A (zh) 2005-03-02
WO2003028527A2 (en) 2003-04-10
AU2002341792B2 (en) 2007-09-06
JP4799820B2 (ja) 2011-10-26
KR20040047846A (ko) 2004-06-05
JP2005505580A (ja) 2005-02-24
US7326685B2 (en) 2008-02-05
US20050070470A1 (en) 2005-03-31
EP1435826A4 (en) 2009-07-15
CA2461099A1 (en) 2003-04-10
EP1435826A2 (en) 2004-07-14
NZ532204A (en) 2006-04-28
WO2003028527A3 (en) 2003-10-30
IL160993A0 (en) 2004-08-31
NO20041186L (no) 2004-05-05
ZA200402698B (en) 2005-04-25
IL160993A (en) 2011-04-28

Similar Documents

Publication Publication Date Title
BR0212897A (pt) Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
EP1792915A3 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
ATE314092T1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
BR0314619A (pt) Análogos de ghrh
WO1999024075A3 (en) Affinity markers for human serum albumin
BR0016051A (pt) ésteres clorofìlicos e bacterioclorofìlicos, sua preparação e composições farmacêuticas que os compreendem
DE69637535D1 (de) Mittel auf basis radiomarkierter peptide zur ortsspezifischen verabreichung
DK1450771T3 (da) Farmaceutiske præparater til behandling af hudlæsioner og slimhinder og fremgangsmåder og kits til anvendelse heraf
WO1998037100A3 (en) Therapeutic use of the smr1 protein and active derivatives thereof
ATE383854T1 (de) Kombination ausgewählter opioide mit muscarin- antagonisten zur therapie der harninkontinenz
BR9812394A (pt) Amino terminalmente truncado mcp-2 como antagonistas da quimiocina
WO1994029337A1 (en) Anti-inflammatory composition and method with des-tyr dynorphin and analogues
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
WO2014130949A1 (en) Methods and compositions for the treatment of bone remodeling disorders
CY1105116T1 (el) Χρηση των il-6r/il-6 χιμαιρων στη νοσο του huntington
BR9810452A (pt) Nova combinação de medicamentos contra asma
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
JP6897971B2 (ja) 関節炎を処置するための、方法および組成物
NO982935D0 (no) Hyaluronsyre reseptor bindende middel og anvendelse derav
PT1128841E (pt) Composicao farmaceutica contendo um antagonista de receptor para o tratamento de disturbios da coagulacao sanguinea
JP2005508875A5 (pt)
WO2002007676A3 (en) Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2167 DE 17/07/2012.